PBLS Latest Press Releases

-- October 24, 2026 --

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors Globe Newswire 8:44 AM

-- October 19, 2026 --

Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 Globe Newswire 7:00 AM

-- October 14, 2026 --

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis Globe Newswire 7:00 AM

-- September 1, 2026 --

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Globe Newswire 7:00 AM

-- August 25, 2026 --

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors Globe Newswire 7:00 AM

-- August 13, 2026 --

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- June 11, 2026 --

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes